Literature DB >> 2828034

Molecular cloning of the lymphocyte activation marker Blast-1.

D E Staunton1, D A Thorley-Lawson.   

Abstract

Blast-1 is an early activation-associated glycoprotein expressed on the surface of human lymphocytes. Here we report the isolation and analysis of a cDNA encoding Blast-1. The translated sequence of the Blast-1 cDNA contains a hydrophobic putative signal peptide and a hydrophobic carboxyl terminus devoid of charged residues. The sequence also contains five N-linked glycosylation sites, the utilization of which was confirmed by the shift in relative mol. wt of Blast-1 upon digestion with N-glycosidase F. The translated sequence reveals that Blast-1 is related to members of the immunoglobulin superfamily, especially to CD4 and MHC class II molecules. The homology to these proteins is greatest in their amino termini where they demonstrate 30-32% identity. This region of Blast-1 also demonstrated 25% identity to a V kappa sequence. Considering conservative amino acid substitutions this homology to CD4, MHC class II and V kappa becomes 60, 49 and 48%, respectively.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2828034      PMCID: PMC553839          DOI: 10.1002/j.1460-2075.1987.tb02703.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  43 in total

1.  Expression of the mouse dihydrofolate reductase complementary deoxyribonucleic acid in simian virus 40 vectors.

Authors:  S Subramani; R Mulligan; P Berg
Journal:  Mol Cell Biol       Date:  1981-09       Impact factor: 4.272

Review 2.  Empirical predictions of protein conformation.

Authors:  P Y Chou; G D Fasman
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

3.  Studies on the efficiency of translation and on the stability of actin messenger ribonucleic acid in mouse sarcoma ascites cells.

Authors:  S Cereghini; T Geoghegan; I Bergmann; G Brawerman
Journal:  Biochemistry       Date:  1979-07-10       Impact factor: 3.162

4.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

5.  Identification of antigenic determinants unique to the surfaces of cells transformed by Epstein-Barr virus.

Authors:  C Kintner; B Sugden
Journal:  Nature       Date:  1981-12-03       Impact factor: 49.962

6.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

7.  Assembly and maturation of HLA-A and HLA-B antigens in vivo.

Authors:  M S Krangel; H T Orr; J L Strominger
Journal:  Cell       Date:  1979-12       Impact factor: 41.582

8.  Polypeptides of the Epstein-Barr virus membrane antigen complex.

Authors:  D A Thorley-Lawson; C M Edson
Journal:  J Virol       Date:  1979-11       Impact factor: 5.103

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  13 in total

1.  The isolation of cDNA clones for CD48.

Authors:  H A Vaughan; M M Henning; D F Purcell; I F McKenzie; M S Sandrin
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

2.  Characterization of genomic polymorphism of an activation-associated antigen, Blast-1.

Authors:  Y Matsui; K Shibano; H Kashiwagi; K Yamakawa-Kobayashi; H Inoko; D E Staunton; D A Thorley-Lawson
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

3.  The detection of Epstein-Barr virus in hairy cell leukemia cells by in situ hybridization.

Authors:  B C Wolf; A W Martin; R S Neiman; A J Janckila; L T Yam; A Caracansi; B A Leav; R Winpenny; D S Schultz; H J Wolfe
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

4.  The mast cell tumor necrosis factor alpha response to FimH-expressing Escherichia coli is mediated by the glycosylphosphatidylinositol-anchored molecule CD48.

Authors:  R Malaviya; Z Gao; K Thankavel; P A van der Merwe; S N Abraham
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 5.  SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions.

Authors:  Cynthia Detre; Marton Keszei; Xavier Romero; George C Tsokos; Cox Terhorst
Journal:  Semin Immunopathol       Date:  2010-02-10       Impact factor: 9.623

6.  Characterization of the Epstein-Barr virus-inducible gene encoding the human leukocyte adhesion and activation antigen BLAST-1 (CD48).

Authors:  R C Fisher; D A Thorley-Lawson
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

7.  The human leucocyte antigen CD48 (MEM-102) is closely related to the activation marker Blast-1.

Authors:  V Korínek; I Stefanová; P Angelisová; I Hilgert; V Horejsí
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

8.  The MRC OX-45 antigen of rat leukocytes and endothelium is in a subset of the immunoglobulin superfamily with CD2, LFA-3 and carcinoembryonic antigens.

Authors:  N Killeen; R Moessner; J Arvieux; A Willis; A F Williams
Journal:  EMBO J       Date:  1988-10       Impact factor: 11.598

9.  Blast-1 possesses a glycosyl-phosphatidylinositol (GPI) membrane anchor, is related to LFA-3 and OX-45, and maps to chromosome 1q21-23.

Authors:  D E Staunton; R C Fisher; M M LeBeau; J B Lawrence; D E Barton; U Francke; M Dustin; D A Thorley-Lawson
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

10.  A soluble multimeric recombinant CD2 protein identifies CD48 as a low affinity ligand for human CD2: divergence of CD2 ligands during the evolution of humans and mice.

Authors:  A R Arulanandam; P Moingeon; M F Concino; M A Recny; K Kato; H Yagita; S Koyasu; E L Reinherz
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.